Altai Capital Management L.P. Purchases Shares of 157,915 OraSure Technologies, Inc. $OSUR

Key Points

• Altai Capital Management L.P. acquired 157,915 shares of OraSure Technologies, Inc. valued at approximately $532,000, making it the firm's 5th largest holding.
• 93.50% of OraSure Technologies' stock is currently owned by institutional investors, indicating significant institutional interest in the company.
• Analysts have given OraSure Technologies a consensus rating of "Hold" with a price target of $3.00, reflecting cautious sentiment towards the stock's performance.

Altai Capital Management L.P. acquired a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 157,915 shares of the medical instruments supplier's stock, valued at approximately $532,000. OraSure Technologies accounts for approximately 0.9% of Altai Capital Management L.P.'s investment portfolio, making the stock its 5th biggest holding. Altai Capital Management L.P. owned about 0.21% of OraSure Technologies at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in OSUR. Price T Rowe Associates Inc. MD increased its position in shares of OraSure Technologies by 5.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 76,932 shares of the medical instruments supplier's stock worth $278,000 after acquiring an additional 3,828 shares during the last quarter. Significant Wealth Partners LLC grew its stake in OraSure Technologies by 20.8% in the first quarter. Significant Wealth Partners LLC now owns 27,067 shares of the medical instruments supplier's stock worth $91,000 after purchasing an additional 4,656 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in OraSure Technologies by 202.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 5,234 shares in the last quarter. ProShare Advisors LLC grew its stake in OraSure Technologies by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 20,327 shares of the medical instruments supplier's stock worth $73,000 after purchasing an additional 6,689 shares in the last quarter. Finally, Graham Capital Management L.P. grew its stake in OraSure Technologies by 17.3% in the fourth quarter. Graham Capital Management L.P. now owns 46,640 shares of the medical instruments supplier's stock worth $168,000 after purchasing an additional 6,882 shares in the last quarter. 93.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on OSUR. Wall Street Zen upgraded OraSure Technologies from a "sell" rating to a "hold" rating in a research note on Saturday, May 17th. Evercore ISI restated an "in-line" rating and issued a $3.00 target price on shares of OraSure Technologies in a research note on Monday, May 19th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $3.00.

OraSure Technologies Stock Up 2.5%

OSUR traded up $0.08 during trading on Friday, reaching $3.23. The stock had a trading volume of 259,845 shares, compared to its average volume of 596,316. The firm has a market capitalization of $236.23 million, a price-to-earnings ratio of -4.82 and a beta of 0.44. OraSure Technologies, Inc. has a 1-year low of $2.36 and a 1-year high of $4.60. The stock has a 50 day moving average of $3.09 and a two-hundred day moving average of $3.08.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.